Protagonist Therapeutics Quarterly Income Statements Chart
Quarterly
|
Annual
Protagonist Therapeutics Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| license and collaboration revenue | 5,546,000 | 28,321,000 | 170,638,000 | 4,675,000 | 4,167,000 | 254,953,000 | |||||||||||||||||||||||||||||||
| operating expenses: | |||||||||||||||||||||||||||||||||||||
| research and development | 37,036,000 | 35,893,000 | 34,904,000 | 35,970,000 | 33,520,000 | 33,734,000 | 28,899,000 | 30,664,000 | 33,182,000 | 27,416,000 | 29,884,000 | 25,402,000 | 34,611,000 | 36,318,000 | 38,373,000 | 36,956,000 | 26,432,000 | 24,245,000 | 19,486,000 | 15,995,000 | 20,257,000 | 18,768,000 | 15,911,000 | 17,293,000 | 19,355,000 | 12,444,000 | 14,248,000 | 12,145,000 | 17,735,000 | 15,368,000 | 11,724,000 | 11,168,000 | 12,007,000 | 11,282,000 | 8,823,000 | 5,561,000 | 5,696,000 |
| general and administrative | 10,551,000 | 11,738,000 | 8,954,000 | 10,158,000 | 9,440,000 | 14,910,000 | 8,052,000 | 7,662,000 | 9,172,000 | 8,605,000 | 6,632,000 | 6,901,000 | 7,691,000 | 10,515,000 | 7,260,000 | 7,256,000 | 6,715,000 | 5,965,000 | 4,994,000 | 4,891,000 | 4,177,000 | 4,576,000 | 4,107,000 | 4,015,000 | 3,863,000 | 3,764,000 | 3,517,000 | 3,361,000 | 3,178,000 | 3,642,000 | 3,071,000 | 2,593,000 | 3,124,000 | 2,991,000 | 2,574,000 | 1,577,000 | 1,395,000 |
| total operating expenses | 47,587,000 | 47,631,000 | 43,858,000 | 46,128,000 | 42,960,000 | 48,644,000 | 36,951,000 | 38,326,000 | 42,354,000 | 36,021,000 | 36,516,000 | 32,303,000 | 42,302,000 | 46,833,000 | 45,633,000 | 44,212,000 | 33,147,000 | 30,210,000 | 24,480,000 | 20,886,000 | 24,434,000 | 23,344,000 | 20,018,000 | 21,308,000 | 23,218,000 | 16,208,000 | 17,765,000 | 15,506,000 | 20,913,000 | 19,010,000 | 14,795,000 | 13,761,000 | 15,131,000 | 14,273,000 | 11,397,000 | 7,138,000 | 7,091,000 |
| income from operations | -42,041,000 | -19,310,000 | 126,780,000 | -41,453,000 | -38,793,000 | 206,309,000 | 23,049,000 | -38,326,000 | -42,354,000 | -36,021,000 | -36,516,000 | -32,303,000 | -41,443,000 | -21,111,000 | -37,016,000 | -33,926,000 | -30,882,000 | -24,021,000 | -18,830,000 | -7,772,000 | -18,217,000 | -19,697,000 | -17,299,000 | -17,167,000 | -31,407,000 | -14,648,000 | -15,412,000 | -9,389,000 | -9,239,000 | -8,229,000 | -3,513,000 | -4,980,000 | -15,131,000 | -14,273,000 | -11,397,000 | -7,138,000 | -7,091,000 |
| yoy | 8.37% | -109.36% | 450.05% | 8.16% | -8.41% | -672.75% | -163.12% | 18.65% | 2.20% | 70.63% | -1.35% | -4.78% | 34.20% | -12.11% | 96.58% | 336.52% | 69.52% | 21.95% | 8.85% | -54.73% | -42.00% | 34.47% | 12.24% | 82.84% | 239.94% | 78.00% | 338.71% | 88.53% | -38.94% | -42.35% | -69.18% | -30.23% | 113.38% | ||||
| qoq | 117.72% | -115.23% | -405.84% | 6.86% | -118.80% | 795.09% | -160.14% | -9.51% | 17.58% | -1.36% | 13.04% | -22.05% | 96.31% | -42.97% | 9.11% | 9.86% | 28.56% | 27.57% | 142.28% | -57.34% | -7.51% | 13.86% | 0.77% | -45.34% | 114.41% | -4.96% | 64.15% | 1.62% | 12.27% | 134.24% | -29.46% | -67.09% | 6.01% | 25.23% | 59.67% | 0.66% | |
| operating margin % | |||||||||||||||||||||||||||||||||||||
| interest income | 7,406,000 | 7,573,000 | 6,853,000 | 7,682,000 | 7,404,000 | 4,376,000 | 4,242,000 | 4,252,000 | 3,913,000 | 2,491,000 | 2,251,000 | 1,157,000 | 484,000 | 168,000 | 122,000 | 122,000 | 97,000 | 102,000 | 80,000 | 87,000 | 207,000 | 526,000 | 604,000 | 728,000 | 748,000 | 654,000 | 576,000 | 568,000 | 461,000 | 155,000 | 152,000 | 172,000 | 149,000 | 54,000 | 27,000 | ||
| other income | 36,000 | 82,000 | 31,000 | 141,000 | 97,000 | -19,000 | 44,000 | -31,000 | -19,000 | -195,000 | 71,000 | -86,000 | -78,000 | 13,000 | -13,000 | -57,000 | -79,000 | -9,000 | -59,000 | 512,000 | -490,000 | -34,000 | |||||||||||||||
| income before income tax benefit | -34,599,000 | 36,436,000 | -33,630,000 | -31,292,000 | -18,886,000 | -7,763,000 | -18,292,000 | -16,645,000 | -16,511,000 | -30,803,000 | |||||||||||||||||||||||||||
| income tax benefit | 172,000 | -557,500 | 420,000 | 676,000 | -1,129,000 | -856,000 | 102,000 | 1,629,000 | |||||||||||||||||||||||||||||
| net income | -34,771,000 | -11,655,000 | 131,674,000 | -33,210,000 | -30,616,000 | 207,340,000 | 27,335,000 | -34,105,000 | -38,460,000 | -33,725,000 | -34,194,000 | -31,232,000 | -41,037,000 | -20,930,000 | -36,907,000 | -33,804,000 | -30,842,000 | -23,998,000 | -18,886,000 | -7,763,000 | -19,421,000 | -20,080,000 | -17,501,000 | -16,409,000 | -29,174,000 | -14,103,000 | -13,865,000 | -8,735,000 | -8,663,000 | -7,661,000 | -3,052,000 | -4,825,000 | -14,979,000 | -14,101,000 | -11,248,000 | -7,084,000 | -7,098,000 |
| yoy | 13.57% | -105.62% | 381.70% | -2.62% | -20.40% | -714.80% | -179.94% | 9.20% | -6.28% | 61.13% | -7.35% | -7.61% | 33.06% | -12.78% | 95.42% | 335.45% | 58.81% | 19.51% | 7.91% | -52.69% | -33.43% | 42.38% | 26.22% | 87.85% | 236.77% | 84.09% | 354.29% | 81.04% | -42.17% | -45.67% | -72.87% | -31.89% | 111.03% | ||||
| qoq | 198.34% | -108.85% | -496.49% | 8.47% | -114.77% | 658.51% | -180.15% | -11.32% | 14.04% | -1.37% | 9.48% | -23.89% | 96.07% | -43.29% | 9.18% | 9.60% | 28.52% | 27.07% | 143.28% | -60.03% | -3.28% | 14.74% | 6.65% | -43.75% | 106.86% | 1.72% | 58.73% | 0.83% | 13.08% | 151.02% | -36.75% | -67.79% | 6.23% | 25.36% | 58.78% | -0.20% | |
| net income margin % | |||||||||||||||||||||||||||||||||||||
| net income per share | -0.55 | -0.19 | 2.13 | -0.54 | -0.5 | 3.41 | 0.52 | -0.58 | -0.68 | -0.67 | -0.7 | -0.64 | -0.84 | -0.43 | -0.77 | -0.7 | -0.69 | -0.54 | -0.47 | -0.21 | -0.59 | -0.72 | -0.62 | -0.61 | -1.18 | -0.58 | -0.59 | -0.38 | -0.41 | -0.36 | -0.08 | -0.29 | -0.89 | -0.84 | 2.82 | -0.87 | -19.07 |
| weighted-average shares used for eps calculation | 63,510,537 | 62,963,806 | 61,566,989 | 61,767,934 | 61,305,289 | 60,855,689 | 56,763,559 | 59,182,899 | 56,775,742 | 50,573,650 | 49,042,232 | 49,107,639 | 49,049,902 | 48,752,548 | 46,322,910 | 47,987,184 | 44,864,637 | 44,224,169 | 34,396,446 | 37,386,881 | 32,799,691 | 27,703,918 | 25,894,024 | 26,956,957 | 24,662,779 | 24,297,576 | 22,364,515 | 22,912,279 | 21,207,234 | 21,112,393 | 17,694,505 | 16,911,575 | 16,875,627 | 16,766,218 | 6,501,796 | 8,483,189 | 383,910 |
| income before income tax expense | -11,655,000 | 210,666,000 | -22,161,000 | -33,804,000 | -30,842,000 | -23,998,000 | -19,904,000 | -13,920,000 | |||||||||||||||||||||||||||||
| income tax expense | -3,326,000 | -176,000 | -183,000 | ||||||||||||||||||||||||||||||||||
| license and collaboration revenue - related party | 6,645,250 | 859,000 | 25,722,000 | 8,617,000 | 10,286,000 | 2,265,000 | 6,189,000 | 5,650,000 | 13,114,000 | 6,217,000 | 3,647,000 | 2,719,000 | 4,141,000 | -8,189,000 | 1,560,000 | 2,353,000 | 6,117,000 | 11,674,000 | 10,781,000 | 11,282,000 | 8,781,000 | ||||||||||||||||
| interest expense | -127,000 | -19,000 | -209,000 | -243,000 | |||||||||||||||||||||||||||||||||
| loss on early repayment of debt | -585,000 | ||||||||||||||||||||||||||||||||||||
| interest income and other | 497,250 | 656,000 | |||||||||||||||||||||||||||||||||||
| change in fair value of redeemable convertible preferred stock tranche and warrant liabilities | |||||||||||||||||||||||||||||||||||||
| net income attributable to common stockholders | -3,052,000 | -4,825,000 | -14,979,000 | -14,101,000 | -11,248,000 | -7,377,000 | -7,323,000 |
We provide you with 20 years income statements for Protagonist Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Protagonist Therapeutics stock. Explore the full financial landscape of Protagonist Therapeutics stock with our expertly curated income statements.
The information provided in this report about Protagonist Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.